Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Botnar Research Centre, University of Oxford, Windmill Road, Headington, Oxford, OX3 7LD, UK.
Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK.
Qual Life Res. 2019 Feb;28(2):335-343. doi: 10.1007/s11136-018-1978-1. Epub 2018 Sep 18.
The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a commonly used outcome measure for osteoarthritis. There are different versions of the WOMAC (Likert, visual analogue or numeric scales). A previous review of trials published before 2010 found poor reporting and inconsistency in how the WOMAC was used. This review explores whether these problems persist.
This systematic review included randomised trials of hip and/or knee osteoarthritis published in 2016 that used the WOMAC. Data were extracted on the version used, score range, analysis and results of the WOMAC, and whether these details were clearly reported.
This review included 62 trials and 41 reported the WOMAC total score. The version used and item range for the WOMAC total score were unclear in 44% (n = 18/41) and 24% (n = 10/41) of trials, respectively. The smallest total score range was 0-10 (calculated by averaging 24 items scored 0-10); the largest was 0-2400 (calculated by summing 24 items scored 0-100). All trials reported the statistical analysis methods but only 29% reported the between-group mean difference and 95% confidence interval.
Details on the use and scoring of the WOMAC were often not reported. We recommend that trials report the version of the WOMAC and the score range used. The between-group treatment effect and corresponding confidence interval should be reported. If all the items of the WOMAC are collected, the total score and individual subscale scores should be presented. Better reporting would facilitate the interpretation, comparison and synthesis of the WOMAC score in trials.
西安大略省和麦克马斯特大学骨关节炎指数(WOMAC)是一种常用于骨关节炎的结果测量方法。WOMAC 有不同的版本(李克特、视觉模拟或数字量表)。2010 年之前发表的试验的先前综述发现,WOMAC 的使用报告和一致性较差。本次综述探讨了这些问题是否仍然存在。
本系统综述包括 2016 年发表的使用 WOMAC 的髋部和/或膝部骨关节炎随机试验。提取使用的版本、评分范围、WOMAC 的分析和结果,以及这些细节是否得到明确报告的数据。
本综述纳入了 62 项试验,其中 41 项报告了 WOMAC 总分。44%(n=18/41)和 24%(n=10/41)的试验对 WOMAC 总分使用的版本和项目范围不清楚。WOMAC 总分的最小评分范围为 0-10(通过平均 24 个评分为 0-10 的项目计算得出);最大为 0-2400(通过加总 24 个评分为 0-100 的项目计算得出)。所有试验均报告了统计分析方法,但仅有 29%报告了组间平均差异和 95%置信区间。
WOMAC 的使用和评分细节通常未得到报告。我们建议试验报告 WOMAC 的版本和使用的评分范围。应报告组间治疗效果及其相应的置信区间。如果收集了 WOMAC 的所有项目,则应呈现总分和各子量表分数。更好的报告将有助于解释、比较和综合试验中的 WOMAC 评分。